Research and Development

We pride ourselves on bringing together the most qualified, passionate experts in the biopharmaceutical industry, to produce medical products that can treat a variety of diseases and medical conditions.

Inhouse Capabilities

Our goal is to provide cost effective, standardised, affordable medicines. We are leaders in the conceptualisation, formulation, and the creation of products that are consistent, compliant, plant-derived medicines. We want to perfect the usage of nature in medicine via a robust clinical pipeline.

Collaborative efforts

We work with some of the brightest professionals in the biopharmaceutical industry as well as leading hospitals and clinical researchers across the globe, to produce the highest quality products that make up our clinical pipeline.

Academic Foundations

MGC Pharma has built strong relationships with the Royal Melbourne Institute of Technology and the Slovenian National Institute of Biology, to produce the most rigorous research and develop a high-quality clinical pipeline.

Our Partners and Collaborators

We partner with leading institutions, companies and groups worldwide, to support expanding the agenda of plant-based medicines supporting unmet needs.

Research, Clinical and Academia

Education & Patient Access Partners

Distribution, Logistics, Manufacturing

Our R&D offering​​

Research and Development is at the heart of everything we do as a business. Our products have been brought to the level of API (Active Pharmaceutical Ingredient) through a careful and regulated process of isolation and purification. The research and development involved in this process are the building blocks of MGC’s medicines, and we believe they hold the key to more effective treatments for patients all over the world. MGC’s research and development projects include preclinical, clinical, botanical development and novel drug delivery systems, focused at the intersection of plant-derived medicines and the pharmaceutical industry.

Leading the global shift towards plant-based, naturally harmonious medicines, improving lives and public health.

Rob Clements

Chief Commercial Officer

After starting his career with an initial spell in the City of London Rob joined the pharmaceutical industry in 1991. Over the following decade he progressed rapidly through field roles to Marketing Management. He then established his own consultancy specialising in relationship marketing and product launch for healthcare companies.

He subsequently worked in business development roles identifying potential product acquisitions – both prescription and OTC – the development and launch of medical devices and general strategic functions. His roles included improving business performance and company morale, and oversight of companies’ core marketing of ethical brands.

From 2011 Rob headed a pan-national team for Forest Laboratories delivering new ethical products to markets alongside management of the existing portfolio. As Director both of Marketing and Commercial operations he was also directly responsible for budgeting, planning and data provision, whilst remaining closely involved with the assessment of BD opportunities.

An expert in specialist disease marketing and business development Rob has also worked extensively on a number of proposed private equity asset buyouts in addition to previous consultancy work.

From 2019 he worked with Healthcare at Home (now Sciensus Rare) to help establish an international rare medicines division. As Vice President of Business Development his role included ongoing development and refinement of the service offering and building new business opportunities; from strategic partnerships and potential MA acquisitions through to establishing Sciensus Rare’s global footprint.